Pervasis Therapeutics Secures $10M in New Financing
Summary
Pervasis Therapeutics Secures $10M in New Financing Xconomy Boston — Pervasis Therapeutics, a Cambridge, MA-based developer of drugs to heal blood vessels, has raised $10 million of a proposed $17.4 million round of private equity financing, according to an SEC filing.The startup names the prolific MIT inventor Bob Langer among its board members.This latest deal appears to be a Series C round of financing, based on the financial news that Pervasis has previously announced.Luke took a more in-depth look at Pervasis’ technology when talked to company CEO Frederick Chereau, a former Genzyme (NASDAQ:GENZ) executive, last October.The company’s lead drug, Vascugel, is in clinical development to help repair of blood vessels in kidney disease patients who are on dialysis.